{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T09:47:38Z","timestamp":1783590458229,"version":"3.55.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T00:00:00Z","timestamp":1731369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T00:00:00Z","timestamp":1731369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["Ricerca Corrente"],"award-info":[{"award-number":["Ricerca Corrente"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>A strict association exists between mood disorders and endogenous hypercortisolism, namely Cushing\u2019s syndrome (CS). Indeed, CS is characterized by a wide range of mood disorders, such as major depression, generalized anxiety, panic disorders, bipolar disorders up to psychosis, with major depression being the most frequent, with a prevalence of 50\u201380%, and potentially representing the clinical onset of disease. Despite this observation, the exact prevalence of hypercortisolism in patients with mood disorders is unknown and who\/how to screen for endogenous hypercortisolism among patients with mood disorders is still unclear. In this context, an accurate anamnestic and clinical examination are crucial in order to identify those patients who may benefit from CS screening. In particular, the presence of specific signs and symptoms of CS, comorbidities typically associated with CS, and lack of improvement of depressive symptoms with standard treatments can further guide the decision to screen for CS. Anyhow, it is noteworthy that mood disorders represent a cause of functional activation of hypothalamic-pituitary-adrenal (HPA) axis, a condition formerly known as non-neoplastic hypercortisolism (NNH). The differential diagnosis between CS and NNH is challenging. Beyond anamnestic and clinical features, various tests, including measurement of daily urinary cortisol and late-night salivary cortisol, together with low dose-dexamethasone suppression test, are used for initial screening. However, considering their low accuracy, a definitive diagnosis may require a longitudinal follow-up along with second-line dynamic tests like combined dexamethasone-CRH test and desmopressin test. In conclusion, available data suggest the need for a comprehensive assessment and follow-up of individuals with mood disorders to detect possible underlying CS, considering the pitfalls in diagnosis and the overlap of symptoms with other conditions like NNH. Specialized centers with expertise in CS diagnosis and differential testing are recommended for accurate evaluation and management of these patients.<\/jats:p>","DOI":"10.1007\/s40618-024-02457-5","type":"journal-article","created":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T10:01:32Z","timestamp":1731405692000},"page":"75-82","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Who and how to screen for endogenous hypercortisolism in patients with mood disorders"],"prefix":"10.1007","volume":"48","author":[{"given":"Emanuele","family":"Ferrante","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Simeoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Mantovani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9632-1348","authenticated-orcid":false,"given":"Rosario","family":"Pivonello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,12]]},"reference":[{"key":"2457_CR1","doi-asserted-by":"publisher","unstructured":"Pivonello R, Simeoli C, De Martino MC et al (2015) Neuropsychiatric disorders in Cushing\u2019s syndrome. Front Neurosci 9. https:\/\/doi.org\/10.3389\/fnins.2015.00129","DOI":"10.3389\/fnins.2015.00129"},{"key":"2457_CR2","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1176\/ajp.142.8.911","volume":"142","author":"RF Haskett","year":"1985","unstructured":"Haskett RF (1985) Diagnostic categorization of psychiatric disturbance in Cushing\u2019s syndrome. Am J Psychiatry 142:911\u2013916. https:\/\/doi.org\/10.1176\/ajp.142.8.911","journal-title":"Am J Psychiatry"},{"key":"2457_CR3","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1176\/ajp.144.7.951","volume":"144","author":"JI Hudson","year":"1987","unstructured":"Hudson JI, Hudson MS, Griffing GT et al (1987) Phenomenology and family history of affective disorder in Cushing\u2019s disease. Am J Psychiatry 144:951\u2013953. https:\/\/doi.org\/10.1176\/ajp.144.7.951","journal-title":"Am J Psychiatry"},{"key":"2457_CR4","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1055\/s-2007-1014405","volume":"25","author":"PT Loosen","year":"1992","unstructured":"Loosen PT, Chambliss B, DeBold CR et al (1992) Psychiatric phenomenology in Cushing\u2019s disease. Pharmacopsychiatry 25:192\u2013198. https:\/\/doi.org\/10.1055\/s-2007-1014405","journal-title":"Pharmacopsychiatry"},{"key":"2457_CR5","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1159\/000182736","volume":"39","author":"N Sonino","year":"1993","unstructured":"Sonino N, Fava GA, Belluardo P et al (1993) Course of depression in Cushing\u2019s syndrome: response to treatment and comparison with Graves\u2019 disease. Horm Res 39:202\u2013206. https:\/\/doi.org\/10.1159\/000182736","journal-title":"Horm Res"},{"key":"2457_CR6","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1159\/000029054","volume":"31","author":"N Sonino","year":"1998","unstructured":"Sonino N, Fava GA, Raffi AR et al (1998) Clinical correlates of Major Depression in Cushing\u2019s Disease. Psychopathology 31:302\u2013306. https:\/\/doi.org\/10.1159\/000029054","journal-title":"Psychopathology"},{"key":"2457_CR7","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1111\/j.1365-2265.1995.tb02614.x","volume":"43","author":"LD Dorn","year":"1995","unstructured":"Dorn LD, Burgess ES, Dubbert B et al (1995) Psychopathology in patients with endogenous Cushing\u2019s syndrome: \u2018atypical\u2019 or melancholic features. Clin Endocrinol (Oxf) 43:433\u2013442. https:\/\/doi.org\/10.1111\/j.1365-2265.1995.tb02614.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2457_CR8","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1093\/qjmed\/89.7.543","volume":"89","author":"WF Kelly","year":"1996","unstructured":"Kelly WF (1996) Psychiatric aspects of Cushing\u2019s syndrome. QJM Mon J Assoc Physicians 89:543\u2013551. https:\/\/doi.org\/10.1093\/qjmed\/89.7.543","journal-title":"QJM Mon J Assoc Physicians"},{"key":"2457_CR9","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1007\/s40265-017-0735-z","volume":"77","author":"A Santos","year":"2017","unstructured":"Santos A, Resmini E, Pascual JC et al (2017) Psychiatric symptoms in patients with Cushing\u2019s syndrome: prevalence, diagnosis and management. Drugs 77:829\u2013842. https:\/\/doi.org\/10.1007\/s40265-017-0735-z","journal-title":"Drugs"},{"key":"2457_CR10","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.ecl.2013.05.010","volume":"42","author":"MN Starkman","year":"2013","unstructured":"Starkman MN (2013) Neuropsychiatric findings in Cushing syndrome and exogenous glucocorticoid administration. Endocrinol Metab Clin North Am 42:477\u2013488. https:\/\/doi.org\/10.1016\/j.ecl.2013.05.010","journal-title":"Endocrinol Metab Clin North Am"},{"key":"2457_CR11","doi-asserted-by":"publisher","first-page":"361","DOI":"10.2165\/00023210-200115050-00003","volume":"15","author":"N Sonino","year":"2001","unstructured":"Sonino N, Fava GA (2001) Psychiatric disorders associated with Cushing\u2019s syndrome. Epidemiology, pathophysiology and treatment. CNS Drugs 15:361\u2013373. https:\/\/doi.org\/10.2165\/00023210-200115050-00003","journal-title":"CNS Drugs"},{"key":"2457_CR12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/00006842-198102000-00002","volume":"43","author":"MN Starkman","year":"1981","unstructured":"Starkman MN, Schteingart DE, Schork MA (1981) Depressed mood and other psychiatric manifestations of Cushing\u2019s syndrome: relationship to hormone levels. Psychosom Med 43:3\u201318. https:\/\/doi.org\/10.1097\/00006842-198102000-00002","journal-title":"Psychosom Med"},{"key":"2457_CR13","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1210\/jc.2008-0125","volume":"93","author":"LK Nieman","year":"2008","unstructured":"Nieman LK, Biller BMK, Findling JW et al (2008) The diagnosis of Cushing\u2019s syndrome: an endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 93:1526\u20131540. https:\/\/doi.org\/10.1210\/jc.2008-0125","journal-title":"J Clin Endocrinol Metab"},{"key":"2457_CR14","doi-asserted-by":"publisher","first-page":"M33","DOI":"10.1530\/EJE-15-0464","volume":"173","author":"LK Nieman","year":"2015","unstructured":"Nieman LK (2015) Cushing\u2019s syndrome: update on signs, symptoms and biochemical screening. Eur J Endocrinol 173:M33\u201338. https:\/\/doi.org\/10.1530\/EJE-15-0464","journal-title":"Eur J Endocrinol"},{"key":"2457_CR15","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1210\/jc.2015-1818","volume":"100","author":"LK Nieman","year":"2015","unstructured":"Nieman LK, Biller BMK, Findling JW et al (2015) Treatment of Cushing\u2019s syndrome: an endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 100:2807\u20132831. https:\/\/doi.org\/10.1210\/jc.2015-1818","journal-title":"J Clin Endocrinol Metab"},{"key":"2457_CR16","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/S2213-8587(16)00086-3","volume":"4","author":"R Pivonello","year":"2016","unstructured":"Pivonello R, Isidori AM, De Martino MC et al (2016) Complications of Cushing\u2019s syndrome: state of the art. Lancet Diabetes Endocrinol 4:611\u2013629. https:\/\/doi.org\/10.1016\/S2213-8587(16)00086-3","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2457_CR17","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1192\/bjp.136.2.120","volume":"136","author":"SI Cohen","year":"1980","unstructured":"Cohen SI (1980) Cushing\u2019s syndrome: a psychiatric study of 29 patients. Br J Psychiatry J Ment Sci 136:120\u2013124. https:\/\/doi.org\/10.1192\/bjp.136.2.120","journal-title":"Br J Psychiatry J Ment Sci"},{"key":"2457_CR18","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1046\/j.1365-2265.1996.8690878.x","volume":"45","author":"WF Kelly","year":"1996","unstructured":"Kelly WF, Kelly MJ, Faragher B (1996) A prospective study of psychiatric and psychological aspects of Cushing\u2019s syndrome. Clin Endocrinol (Oxf) 45:715\u2013720. https:\/\/doi.org\/10.1046\/j.1365-2265.1996.8690878.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2457_CR19","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1210\/jcem.82.3.3834","volume":"82","author":"LD Dorn","year":"1997","unstructured":"Dorn LD, Burgess ES, Friedman TC et al (1997) The longitudinal course of psychopathology in Cushing\u2019s syndrome after correction of hypercortisolism. J Clin Endocrinol Metab 82:912\u2013919. https:\/\/doi.org\/10.1210\/jcem.82.3.3834","journal-title":"J Clin Endocrinol Metab"},{"key":"2457_CR20","first-page":"465","volume":"48","author":"WJ Jeffcoate","year":"1979","unstructured":"Jeffcoate WJ, Silverstone JT, Edwards CR, Besser GM (1979) Psychiatric manifestations of Cushing\u2019s syndrome: response to lowering of plasma cortisol. Q J Med 48:465\u2013472","journal-title":"Q J Med"},{"key":"2457_CR21","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0033-3182(85)72906-4","volume":"26","author":"KG Kramlinger","year":"1985","unstructured":"Kramlinger KG, Peterson GC, Watson PK, Leonard LL (1985) Metyrapone for depression and delirium secondary to Cushing\u2019s syndrome. Psychosomatics 26:67. https:\/\/doi.org\/10.1016\/S0033-3182(85)72906-4","journal-title":"Psychosomatics"},{"key":"2457_CR22","doi-asserted-by":"publisher","first-page":"143","DOI":"10.7326\/0003-4819-114-2-143","volume":"114","author":"AJ van der Lely","year":"1991","unstructured":"van der Lely AJ, Foeken K, van der Mast RC, Lamberts SW (1991) Rapid reversal of acute psychosis in the Cushing syndrome with the cortisol-receptor antagonist mifepristone (RU 486). Ann Intern Med 114:143\u2013144. https:\/\/doi.org\/10.7326\/0003-4819-114-2-143","journal-title":"Ann Intern Med"},{"key":"2457_CR23","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0165-1781(86)90096-x","volume":"19","author":"MN Starkman","year":"1986","unstructured":"Starkman MN, Schteingart DE, Schork MA (1986) Cushing\u2019s syndrome after treatment: changes in cortisol and ACTH levels, and amelioration of the depressive syndrome. Psychiatry Res 19:177\u2013188. https:\/\/doi.org\/10.1016\/0165-1781(86)90096-x","journal-title":"Psychiatry Res"},{"key":"2457_CR24","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s12020-018-1819-6","volume":"64","author":"MH Schernthaner-Reiter","year":"2019","unstructured":"Schernthaner-Reiter MH, Siess C, Gessl A et al (2019) Factors predicting long-term comorbidities in patients with Cushing\u2019s syndrome in remission. Endocrine 64:157\u2013168. https:\/\/doi.org\/10.1007\/s12020-018-1819-6","journal-title":"Endocrine"},{"key":"2457_CR25","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1210\/clinem\/dgab079","volume":"106","author":"D Bengtsson","year":"2021","unstructured":"Bengtsson D, Ragnarsson O, Berinder K et al (2021) Psychotropic drugs in patients with Cushing\u2019s Disease before diagnosis and at Long-Term Follow-Up: a Nationwide Study. J Clin Endocrinol Metab 106:1750\u20131760. https:\/\/doi.org\/10.1210\/clinem\/dgab079","journal-title":"J Clin Endocrinol Metab"},{"key":"2457_CR26","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/S2213-8587(21)00235-7","volume":"9","author":"M Fleseriu","year":"2021","unstructured":"Fleseriu M, Auchus R, Bancos I et al (2021) Consensus on diagnosis and management of Cushing\u2019s disease: a guideline update. Lancet Diabetes Endocrinol 9:847\u2013875. https:\/\/doi.org\/10.1016\/S2213-8587(21)00235-7","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2457_CR27","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1007\/s11102-022-01214-2","volume":"25","author":"H Raff","year":"2022","unstructured":"Raff H (2022) Late Night Salivary Cortisol in the diagnosis of neoplastic hypercortisolism (including cyclic Cushing\u2019s syndrome). Pituitary 25:698\u2013700. https:\/\/doi.org\/10.1007\/s11102-022-01214-2","journal-title":"Pituitary"},{"key":"2457_CR28","doi-asserted-by":"publisher","first-page":"R205","DOI":"10.1530\/EJE-16-0946","volume":"176","author":"JW Findling","year":"2017","unstructured":"Findling JW, Raff H (2017) DIAGNOSIS OF ENDOCRINE DISEASE: differentiation of pathologic\/neoplastic hypercortisolism (Cushing\u2019s syndrome) from physiologic\/non-neoplastic hypercortisolism (formerly known as pseudo-cushing\u2019s syndrome). Eur J Endocrinol 176:R205\u2013R216. https:\/\/doi.org\/10.1530\/EJE-16-0946","journal-title":"Eur J Endocrinol"},{"key":"2457_CR29","doi-asserted-by":"publisher","first-page":"R1","DOI":"10.1530\/EC-19-0435","volume":"9","author":"C Scaroni","year":"2020","unstructured":"Scaroni C, Albiger NM, Palmieri S et al (2020) Approach to patients with pseudo-cushing\u2019s states. Endocr Connect 9:R1\u2013R13. https:\/\/doi.org\/10.1530\/EC-19-0435","journal-title":"Endocr Connect"},{"key":"2457_CR30","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/j.1365-2265.2006.02717.x","volume":"66","author":"F Pecori Giraldi","year":"2007","unstructured":"Pecori Giraldi F, Pivonello R, Ambrogio AG et al (2007) The dexamethasone-suppressed corticotropin-releasing hormone stimulation test and the desmopressin test to distinguish Cushing\u2019s syndrome from pseudo-cushing\u2019s states. Clin Endocrinol (Oxf) 66:251\u2013257. https:\/\/doi.org\/10.1111\/j.1365-2265.2006.02717.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2457_CR31","doi-asserted-by":"publisher","first-page":"4851","DOI":"10.1210\/jc.2009-1500","volume":"94","author":"E Valassi","year":"2009","unstructured":"Valassi E, Swearingen B, Lee H et al (2009) Concomitant medication use can confound interpretation of the combined dexamethasone-corticotropin releasing hormone test in Cushing\u2019s syndrome. J Clin Endocrinol Metab 94:4851\u20134859. https:\/\/doi.org\/10.1210\/jc.2009-1500","journal-title":"J Clin Endocrinol Metab"},{"key":"2457_CR32","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1530\/EJE-13-0702","volume":"170","author":"RA Alwani","year":"2014","unstructured":"Alwani RA, Schmit Jongbloed LW, de Jong FH et al (2014) Differentiating between Cushing\u2019s disease and pseudo-cushing\u2019s syndrome: comparison of four tests. Eur J Endocrinol 170:477\u2013486. https:\/\/doi.org\/10.1530\/EJE-13-0702","journal-title":"Eur J Endocrinol"},{"key":"2457_CR33","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1001\/jama.1993.03500170062035","volume":"269","author":"JA Yanovski","year":"1993","unstructured":"Yanovski JA, Cutler GB, Chrousos GP, Nieman LK (1993) Corticotropin-releasing hormone stimulation following low-dose dexamethasone administration. A new test to distinguish Cushing\u2019s syndrome from pseudo-cushing\u2019s states. JAMA 269:2232\u20132238","journal-title":"JAMA"},{"key":"2457_CR34","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1017\/S0033291712000955","volume":"43","author":"J Herbert","year":"2013","unstructured":"Herbert J (2013) Cortisol and depression: three questions for psychiatry. Psychol Med 43:449\u2013469. https:\/\/doi.org\/10.1017\/S0033291712000955","journal-title":"Psychol Med"},{"key":"2457_CR35","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/0165-1781(84)90037-4","volume":"13","author":"U Halbreich","year":"1984","unstructured":"Halbreich U, Asnis GM, Zumoff B et al (1984) Effect of age and sex on cortisol secretion in depressives and normals. Psychiatry Res 13:221\u2013229. https:\/\/doi.org\/10.1016\/0165-1781(84)90037-4","journal-title":"Psychiatry Res"},{"key":"2457_CR36","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/S0893-133X(00)00236-0","volume":"25","author":"EA Young","year":"2001","unstructured":"Young EA, Carlson NE, Brown MB (2001) Twenty-four-hour ACTH and cortisol pulsatility in depressed women. Neuropsychopharmacol off Publ Am Coll Neuropsychopharmacol 25:267\u2013276. https:\/\/doi.org\/10.1016\/S0893-133X(00)00236-0","journal-title":"Neuropsychopharmacol off Publ Am Coll Neuropsychopharmacol"},{"key":"2457_CR37","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.biopsych.2005.10.014","volume":"60","author":"J Keller","year":"2006","unstructured":"Keller J, Flores B, Gomez RG et al (2006) Cortisol circadian rhythm alterations in psychotic major depression. Biol Psychiatry 60:275\u2013281. https:\/\/doi.org\/10.1016\/j.biopsych.2005.10.014","journal-title":"Biol Psychiatry"},{"key":"2457_CR38","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1210\/clinem\/dgaa105","volume":"105","author":"BP Galm","year":"2020","unstructured":"Galm BP, Qiao N, Klibanski A et al (2020) Accuracy of Laboratory tests for the diagnosis of Cushing Syndrome. J Clin Endocrinol Metab 105:2081\u20132094. https:\/\/doi.org\/10.1210\/clinem\/dgaa105","journal-title":"J Clin Endocrinol Metab"},{"key":"2457_CR39","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1210\/edrv-17-2-187","volume":"17","author":"F Holsboer","year":"1996","unstructured":"Holsboer F, Barden N (1996) Antidepressants and hypothalamic-pituitary-adrenocortical regulation. Endocr Rev 17:187\u2013205. https:\/\/doi.org\/10.1210\/edrv-17-2-187","journal-title":"Endocr Rev"},{"key":"2457_CR40","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1210\/jcem.82.1.3689","volume":"82","author":"M Deuschle","year":"1997","unstructured":"Deuschle M, Schweiger U, Weber B et al (1997) Diurnal activity and pulsatility of the hypothalamus-pituitary-adrenal system in male depressed patients and healthy controls. J Clin Endocrinol Metab 82:234\u2013238. https:\/\/doi.org\/10.1210\/jcem.82.1.3689","journal-title":"J Clin Endocrinol Metab"},{"key":"2457_CR41","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1176\/appi.ajp.162.4.807","volume":"162","author":"MJ Portella","year":"2005","unstructured":"Portella MJ, Harmer CJ, Flint J et al (2005) Enhanced early morning salivary cortisol in neuroticism. Am J Psychiatry 162:807\u2013809. https:\/\/doi.org\/10.1176\/appi.ajp.162.4.807","journal-title":"Am J Psychiatry"},{"key":"2457_CR42","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1136\/bmj.3.5613.285","volume":"3","author":"BJ Carroll","year":"1968","unstructured":"Carroll BJ, Martin FI, Davies B (1968) Resistance to suppression by dexamethasone of plasma 11-O.H.C.S. levels in severe depressive illness. Br Med J 3:285\u2013287. https:\/\/doi.org\/10.1136\/bmj.3.5613.285","journal-title":"Br Med J"},{"key":"2457_CR43","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1159\/000235904","volume":"90","author":"B R\u00f6mer","year":"2009","unstructured":"R\u00f6mer B, Lewicka S, Kopf D et al (2009) Cortisol metabolism in depressed patients and healthy controls. Neuroendocrinology 90:301\u2013306. https:\/\/doi.org\/10.1159\/000235904","journal-title":"Neuroendocrinology"},{"key":"2457_CR44","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1530\/EJE-17-0078","volume":"176","author":"G\u00c5 Ueland","year":"2017","unstructured":"Ueland G\u00c5, Methlie P, Kellmann R et al (2017) Simultaneous assay of cortisol and dexamethasone improved diagnostic accuracy of the dexamethasone suppression test. Eur J Endocrinol 176:705\u2013713. https:\/\/doi.org\/10.1530\/EJE-17-0078","journal-title":"Eur J Endocrinol"},{"key":"2457_CR45","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/0002-9343(89)90227-1","volume":"86","author":"O Orbach","year":"1989","unstructured":"Orbach O, Schussler GC (1989) Increased serum cortisol binding in chronic active hepatitis. Am J Med 86:39\u201342. https:\/\/doi.org\/10.1016\/0002-9343(89)90227-1","journal-title":"Am J Med"},{"key":"2457_CR46","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.4158\/EP161512.DSCR","volume":"22","author":"M Fleseriu","year":"2016","unstructured":"Fleseriu M, Hamrahian AH, Hoffman AR, AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY DISEASE STATE CLINICAL REVIEW: DIAGNOSIS OF RECURRENCE IN CUSHING DISEASE (2016) Endocr Pract off J Am Coll Endocrinol Am Assoc Clin Endocrinol 22:1436\u20131448. https:\/\/doi.org\/10.4158\/EP161512.DSCR","journal-title":"Endocr Pract off J Am Coll Endocrinol Am Assoc Clin Endocrinol"},{"key":"2457_CR47","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s11102-022-01249-5","volume":"25","author":"S Petersenn","year":"2022","unstructured":"Petersenn S (2022) Overnight 1\u00a0mg dexamethasone suppression test and 24\u00a0h urine free cortisol-accuracy and pitfalls when screening for Cushing\u2019s syndrome. Pituitary 25:693\u2013697. https:\/\/doi.org\/10.1007\/s11102-022-01249-5","journal-title":"Pituitary"},{"key":"2457_CR48","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1210\/jc.2003-030207","volume":"89","author":"JW Findling","year":"2004","unstructured":"Findling JW, Raff H, Aron DC (2004) The low-dose dexamethasone suppression test: a reevaluation in patients with Cushing\u2019s syndrome. J Clin Endocrinol Metab 89:1222\u20131226. https:\/\/doi.org\/10.1210\/jc.2003-030207","journal-title":"J Clin Endocrinol Metab"},{"key":"2457_CR49","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1007\/s40618-020-01197-6","volume":"43","author":"F Ceccato","year":"2020","unstructured":"Ceccato F, Artusi C, Barbot M et al (2020) Dexamethasone measurement during low-dose suppression test for suspected hypercortisolism: threshold development with and validation. J Endocrinol Invest 43:1105\u20131113. https:\/\/doi.org\/10.1007\/s40618-020-01197-6","journal-title":"J Endocrinol Invest"},{"key":"2457_CR50","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1093\/jalm\/jfaa193","volume":"6","author":"SM Roper","year":"2021","unstructured":"Roper SM (2021) Yield of serum dexamethasone measurement for reducing false-positive results of low-dose dexamethasone suppression testing. J Appl Lab Med 6:480\u2013485. https:\/\/doi.org\/10.1093\/jalm\/jfaa193","journal-title":"J Appl Lab Med"},{"key":"2457_CR51","doi-asserted-by":"publisher","first-page":"4515","DOI":"10.1210\/jc.2002-020534","volume":"87","author":"DA Papanicolaou","year":"2002","unstructured":"Papanicolaou DA, Mullen N, Kyrou I, Nieman LK (2002) Nighttime salivary cortisol: a useful test for the diagnosis of Cushing\u2019s syndrome. J Clin Endocrinol Metab 87:4515\u20134521. https:\/\/doi.org\/10.1210\/jc.2002-020534","journal-title":"J Clin Endocrinol Metab"},{"key":"2457_CR52","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1210\/jc.2005-2143","volume":"91","author":"NM Martin","year":"2006","unstructured":"Martin NM, Dhillo WS, Banerjee A et al (2006) Comparison of the dexamethasone-suppressed corticotropin-releasing hormone test and low-dose dexamethasone suppression test in the diagnosis of Cushing\u2019s syndrome. J Clin Endocrinol Metab 91:2582\u20132586. https:\/\/doi.org\/10.1210\/jc.2005-2143","journal-title":"J Clin Endocrinol Metab"},{"key":"2457_CR53","doi-asserted-by":"publisher","first-page":"4290","DOI":"10.1210\/jc.2006-2829","volume":"92","author":"B Gatta","year":"2007","unstructured":"Gatta B, Chabre O, Cortet C et al (2007) Reevaluation of the combined dexamethasone suppression-corticotropin-releasing hormone test for differentiation of mild cushing\u2019s disease from pseudo-cushing\u2019s syndrome. J Clin Endocrinol Metab 92:4290\u20134293. https:\/\/doi.org\/10.1210\/jc.2006-2829","journal-title":"J Clin Endocrinol Metab"},{"key":"2457_CR54","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1530\/EJE-08-0402","volume":"159","author":"G Reimondo","year":"2008","unstructured":"Reimondo G, Bovio S, Allasino B et al (2008) The combined low-dose dexamethasone suppression corticotropin-releasing hormone test as a tool to rule out Cushing\u2019s syndrome. Eur J Endocrinol 159:569\u2013576. https:\/\/doi.org\/10.1530\/EJE-08-0402","journal-title":"Eur J Endocrinol"},{"key":"2457_CR55","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1530\/EJE-09-0125","volume":"160","author":"G Arnaldi","year":"2009","unstructured":"Arnaldi G, Tirabassi G, Papa R et al (2009) Human corticotropin releasing hormone test performance in the differential diagnosis between Cushing\u2019s disease and pseudo-cushing state is enhanced by combined ACTH and cortisol analysis. Eur J Endocrinol 160:891\u2013898. https:\/\/doi.org\/10.1530\/EJE-09-0125","journal-title":"Eur J Endocrinol"},{"key":"2457_CR56","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1111\/j.1365-2265.2011.04096.x","volume":"75","author":"G Tirabassi","year":"2011","unstructured":"Tirabassi G, Papa R, Faloia E et al (2011) Corticotrophin-releasing hormone and desmopressin tests in the differential diagnosis between Cushing\u2019s disease and pseudo-cushing state: a comparative study. Clin Endocrinol (Oxf) 75:666\u2013672. https:\/\/doi.org\/10.1111\/j.1365-2265.2011.04096.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2457_CR57","doi-asserted-by":"publisher","first-page":"3569","DOI":"10.1210\/jcem.85.10.6862","volume":"85","author":"M Moro","year":"2000","unstructured":"Moro M, Putignano P, Losa M et al (2000) The desmopressin test in the differential diagnosis between Cushing\u2019s disease and pseudo-cushing states. J Clin Endocrinol Metab 85:3569\u20133574. https:\/\/doi.org\/10.1210\/jcem.85.10.6862","journal-title":"J Clin Endocrinol Metab"},{"key":"2457_CR58","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1111\/cen.12661","volume":"82","author":"GAF Rollin","year":"2015","unstructured":"Rollin GAF, Costenaro F, Gerchman F et al (2015) Evaluation of the DDAVP test in the diagnosis of Cushing\u2019s Disease. Clin Endocrinol (Oxf) 82:793\u2013800. https:\/\/doi.org\/10.1111\/cen.12661","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2457_CR59","doi-asserted-by":"publisher","first-page":"dgaa564","DOI":"10.1210\/clinem\/dgaa564","volume":"105","author":"F Ceccato","year":"2020","unstructured":"Ceccato F, Tizianel I, Vedolin CK et al (2020) Human corticotropin-releasing hormone tests: 10 years of real-life experience in pituitary and adrenal disease. J Clin Endocrinol Metab 105:dgaa564. https:\/\/doi.org\/10.1210\/clinem\/dgaa564","journal-title":"J Clin Endocrinol Metab"},{"key":"2457_CR60","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1007\/s11102-022-01222-2","volume":"25","author":"C Scaroni","year":"2022","unstructured":"Scaroni C, Mondin A, Ceccato F (2022) How to rule out non-neoplastic hypercortisolemia (previously known as pseudo-cushing). Pituitary 25:701\u2013704. https:\/\/doi.org\/10.1007\/s11102-022-01222-2","journal-title":"Pituitary"},{"key":"2457_CR61","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1007\/s40618-023-02113-4","volume":"46","author":"F Ceccato","year":"2023","unstructured":"Ceccato F, Di Dalmazi G (2023) Shortage of hCRH for the diagnosis of endogenous CS: the end of an era or the beginning of a new journey? J Endocrinol Invest 46:2189\u20132191. https:\/\/doi.org\/10.1007\/s40618-023-02113-4","journal-title":"J Endocrinol Invest"},{"key":"2457_CR62","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-023-02099-z","author":"A Mondin","year":"2023","unstructured":"Mondin A, Barbot M, Voltan G et al (2023) Second-line tests in the differential diagnosis of neoplastic and non-neoplastic hypercortisolism: a systematic review and meta-analysis. J Endocrinol Invest. https:\/\/doi.org\/10.1007\/s40618-023-02099-z","journal-title":"J Endocrinol Invest"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-024-02457-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-024-02457-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-024-02457-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T09:12:34Z","timestamp":1746004354000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-024-02457-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,12]]},"references-count":62,"journal-issue":{"issue":"S1","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["2457"],"URL":"https:\/\/doi.org\/10.1007\/s40618-024-02457-5","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,12]]},"assertion":[{"value":"4 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no competing interests to declare that are relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}